Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 66.70
+2.20 (3.41%)
Sep 11, 2026, 5:30 PM CET
Basilea Pharmaceutica AG Ratios and Metrics
Market cap in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 828 | 672 | 501 | 423 | 546 | 485 | |
Market Cap Growth | 46.22% | 34.10% | 18.52% | -22.52% | 12.62% | -15.59% |
Enterprise Value | 739 | 641 | 551 | 505 | 636 | 551 |
Last Close Price | 66.70 | 54.70 | 41.35 | 35.30 | 45.80 | 40.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.63 | 16.70 | 6.46 | 40.47 | 44.94 | - |
Forward PE | 15.27 | 13.26 | 10.63 | 15.17 | 98.35 | 225.87 |
PS Ratio | 3.35 | 2.89 | 2.40 | 2.68 | 3.69 | 3.27 |
PB Ratio | 5.10 | 5.25 | 6.19 | -42.28 | -26.35 | -8.27 |
P/TBV Ratio | 5.11 | 5.27 | 6.22 | - | - | - |
P/FCF Ratio | 14.98 | 11.30 | 6.90 | 31.48 | 139.32 | - |
P/OCF Ratio | 14.28 | 10.83 | 6.74 | 29.69 | 77.36 | - |
PEG Ratio | - | 0.25 | 0.38 | 0.13 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.99 | 2.76 | 2.64 | 3.20 | 4.31 | 3.72 |
EV/EBITDA Ratio | 11.72 | 11.85 | 8.68 | 21.78 | 29.31 | 154.82 |
EV/EBIT Ratio | 12.34 | 12.26 | 8.93 | 23.05 | 30.58 | 183.33 |
EV/FCF Ratio | 13.36 | 10.77 | 7.58 | 37.59 | 162.43 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.51 | 0.70 | 1.38 | -12.86 | -9.03 | -3.74 |
Debt / EBITDA Ratio | 1.32 | 1.59 | 1.71 | 5.05 | 7.76 | 41.61 |
Debt / FCF Ratio | 1.51 | 1.50 | 1.54 | 9.57 | 47.76 | - |
Net Debt / Equity Ratio | -0.55 | -0.55 | -0.11 | -6.86 | -4.95 | -1.20 |
Net Debt / EBITDA Ratio | -1.47 | -1.30 | -0.14 | 2.96 | 4.72 | 19.72 |
Net Debt / FCF Ratio | -1.62 | -1.19 | -0.12 | 5.11 | 26.16 | -2.15 |
Asset Turnover | 0.91 | 0.86 | 0.97 | 0.80 | 0.63 | 0.62 |
Inventory Turnover | 6.25 | 5.46 | 3.99 | 4.13 | 4.18 | 5.33 |
Quick Ratio | 5.81 | 4.53 | 3.93 | 2.48 | 1.96 | 1.22 |
Current Ratio | 6.60 | 5.12 | 4.85 | 3.20 | 2.34 | 1.38 |
Return on Equity (ROE) | 39.46% | 38.52% | 218.58% | - | - | - |
Return on Assets (ROA) | 13.69% | 12.10% | 17.89% | 6.95% | 5.56% | 0.79% |
Return on Invested Capital (ROIC) | 73.48% | 70.88% | 62.43% | 16.11% | 19.02% | 2.38% |
Return on Capital Employed (ROCE) | 23.30% | 22.40% | 29.10% | 17.40% | 14.30% | 4.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.32% | 5.99% | 15.48% | 2.47% | 2.23% | -1.41% |
FCF Yield | 6.68% | 8.85% | 14.50% | 3.18% | 0.72% | -6.73% |
Buyback Yield / Dilution | 1.46% | 1.23% | -14.10% | -1.67% | -2.24% | -13.62% |